These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 31703649)

  • 1. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin.
    van der Vorst MJDL; Neefjes ECW; Toffoli EC; Oosterling-Jansen JEW; Vergeer MR; Leemans CR; Kooistra MP; Voortman J; Verheul HMW
    BMC Cancer; 2019 Nov; 19(1):1066. PubMed ID: 31703649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin.
    Patimarattananan T; Nongnuch A; Pattaranutaporn P; Unwanatham N; Jiarpinitnun C; Ngamphaiboon N
    Support Care Cancer; 2021 Feb; 29(2):877-887. PubMed ID: 32524284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
    Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Castro A; Licitra L; Adelstein D; Vermorken JB
    Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer.
    Gulati S; Desai J; Palackdharry SM; Morris JC; Zhu Z; Jandarov R; Riaz MK; Takiar V; Mierzwa M; Gutkind JS; Molinolo A; Desai PB; Sadraei NH; Wise-Draper TM
    Cancer; 2020 Jan; 126(2):354-362. PubMed ID: 31626727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of acute kidney injury and overall survival in patients with postoperative head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of the phase II/III trial of JCOG1008.
    Imamura Y; Kiyota N; Tahara M; Kodaira T; Hayashi R; Nishino H; Asada Y; Mitani H; Iwae S; Nishio N; Onozawa Y; Hanai N; Ohkoshi A; Hara H; Monden N; Nagaoka M; Minami S; Kitabayashi R; Sasaki K; Homma A;
    Cancer Med; 2024 Sep; 13(18):e70235. PubMed ID: 39348265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy.
    Faig J; Haughton M; Taylor RC; D'Agostino RB; Whelen MJ; Porosnicu Rodriguez KA; Bonomi M; Murea M; Porosnicu M
    Am J Clin Oncol; 2018 May; 41(5):432-440. PubMed ID: 27281266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience.
    Cavalieri S; Platini F; Barretta F; Nuzzolese I; Ottini A; Bergamini C; Resteghini C; Colombo E; Iacovelli NA; Franceschini M; Calareso G; Di Pede P; De Feo G; Gandelli M; Toffolatti L; Guglielmo M; Ripamonti CI; Cosmai L; Licitra L; Alfieri S
    Oral Oncol; 2023 Nov; 146():106579. PubMed ID: 37778228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the Risk Factors and Long-Term Consequences of Cisplatin-Associated Acute Kidney Injury: An Observational Cohort Study.
    Bhat ZY; Cadnapaphornchai P; Ginsburg K; Sivagnanam M; Chopra S; Treadway CK; Lin HS; Yoo G; Sukari A; Doshi MD
    PLoS One; 2015; 10(11):e0142225. PubMed ID: 26556481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
    Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
    Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-Arm Phase 2 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Maguire PD; Neal CR; Hardy SM; Schreiber AM
    Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1210-1216. PubMed ID: 29452770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.
    Bauml JM; Vinnakota R; Anna Park YH; Bates SE; Fojo T; Aggarwal C; Limaye S; Damjanov N; Di Stefano J; Ciunci C; Genden EM; Wisnivesky JP; Ferrandino R; Mamtani R; Langer CJ; Cohen RB; Sigel K
    J Natl Cancer Inst; 2019 May; 111(5):490-497. PubMed ID: 30239887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial.
    Imamura Y; Kiyota N; Tahara M; Kodaira T; Hayashi R; Nishino H; Asada Y; Mitani H; Iwae S; Nishio N; Onozawa Y; Hanai N; Ohkoshi A; Hara H; Monden N; Nagaoka M; Minami S; Kitabayashi R; Sasaki K; Homma A;
    Oral Oncol; 2024 Jul; 154():106868. PubMed ID: 38820889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-dependent hemato- and nephrotoxicity in patients with head and neck cancer receiving chemoradiotherapy with weekly cisplatin.
    Weykamp F; Seidensaal K; Rieken S; Green K; Mende S; Zaoui K; Freier K; Adeberg S; Debus J; Welte SE
    Strahlenther Onkol; 2020 Jun; 196(6):515-521. PubMed ID: 31784802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck - a multicentre, retrospective analysis.
    Helfenstein S; Riesterer O; Meier UR; Papachristofilou A; Kasenda B; Pless M; Rothschild SI
    Radiat Oncol; 2019 Feb; 14(1):32. PubMed ID: 30744643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
    Patil VM; Noronha V; Joshi A; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; Mahimkar M; Juvekar S; Arya S; Mahajan A; Agarwal A; Purandare N; Rangarajan V; Balaji A; Chaudhari SV; Banavali S; Kannan S; Bhattacharjee A; D'Cruz AK; Chaturvedi P; Pai PS; Chaukar D; Pantvaidya G; Nair D; Nair S; Deshmukh A; Thiagarajan S; Mathrudev V; Manjrekar A; Dhumal S; Maske K; Bhelekar AS; Nawale K; Chandrasekharan A; Pande N; Goel A; Talreja V; Simha V; Srinivas S; Swami R; Vallathol DH; Dsouza H; Shrirangwar S; Turkar S; Abraham G; Thanky AH; Patel U; Pandey MK; Prabhash K
    Cancer; 2019 Sep; 125(18):3184-3197. PubMed ID: 31150120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer.
    Okano S; Enokida T; Onoe T; Ota Y; Motegi A; Zenda S; Akimoto T; Tahara M
    Int J Clin Oncol; 2019 Jul; 24(7):789-797. PubMed ID: 30796560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial on acute toxicities of weekly vs three-weekly cisplatin-based chemoradiation in head and neck cancer.
    Ameri A; Norouzi S; Sourati A; Azghandi S; Novin K; Taghizadeh-Hesary F
    Cancer Rep (Hoboken); 2022 Jan; 5(1):e1425. PubMed ID: 34101389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients.
    Ishitsuka R; Miyazaki J; Ichioka D; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Kawai K; Nishiyama H
    Clin Exp Nephrol; 2017 Aug; 21(4):732-740. PubMed ID: 27565169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.
    Fayette J; Molin Y; Lavergne E; Montbarbon X; Racadot S; Poupart M; Ramade A; Zrounba P; Ceruse P; Pommier P
    Drug Des Devel Ther; 2015; 9():6203-10. PubMed ID: 26648696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.
    Noronha V; Joshi A; Patil VM; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; D'Cruz AK; Banavali S; Pai PS; Chaturvedi P; Chaukar D; Pande N; Chandrasekharan A; Talreja V; Vallathol DH; Mathrudev V; Manjrekar A; Maske K; Bhelekar AS; Nawale K; Kannan S; Gota V; Bhattacharjee A; Kane S; Juvekar SL; Prabhash K
    J Clin Oncol; 2018 Apr; 36(11):1064-1072. PubMed ID: 29220295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.